Market Cap
$29.6M
EVAX
Evaxion A/S
$3.28 ▲ +2.99%
Prev close $3.18Market cap$29.6M
12-mo target$11.25 (+243.5%)
High Impact Filing (7/10) Biotech & Drug Discovery
Snapshot
The big-picture read on EVAX right now — valuation, ownership and activity at a glance.
Cap Size
Nano Cap
Inst. Holders
8 funds
Inst. Value
$537.7K
Inst. Activity
1 buys / 0 sells
Social Sentiment
40° Cool
SEC Reports
20
Press Releases
16
Price chart 30d +6.7%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 announcement
Sep 14, 2026 SEC Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting
COPENHAGEN, Denmark, October 2, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage Tech
Evaxion announced it is applying its AI-Immunology platform to autoimmune diseases, testing two novel treatment concepts
6-K — Impact 3/10
Evaxion A/S raised $2.1M net through an at-the-market (ATM) offering of 681,268 ADSs at an average price of $3.1987 per
6-K — Impact 5/10
Evaxion reported Q2 2026 results in line with expectations: net loss narrowed to $3.7M (vs $4.8M YoY), cash burn continu
6-K — Impact 4/10
Evaxion will present three-year Phase 2 data for personalized cancer vaccine EVX-01 at ESMO 2026 (Oct 23-27). The third-
Impact 4/10
Evaxion presented new preclinical data at the International Herpesvirus Workshop 2026 for its CMV vaccine program EVX-V1
Impact 3/10
Jun 30, 2026 Inst.
CITADEL ADVISORS LLC — DOUBLED
36,584 shares ($113.4K)
Dec 31, 2025 Inst.
RHUMBLINE ADVISERS — DOUBLED
21,090 shares ($100.6K)
Analyst ratings buy % +1.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Apr 24, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Aug 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Jul 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Jun 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| May 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Apr 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Mar 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Feb 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% |
Price targets
Where 4 covering analysts think EVAX trades over the next 12 months.
$11.25 +243.5% upside Strong Buy
Current$3.28 Low$9.00 Median$10.00 High$16.00 4 analysts
$9.00$16.00
Analyst rating None as of Oct 2, 2026
Social media sentiment
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
40°
Cool
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
20 SEC filing reports analyzed · 4 bullish, 1 bearish, 0 mixed, 15 neutral · avg impact 3.9/10.Plus 16 press releases.
NEUTRAL6-K3/10
Evaxion announced it is applying its AI-Immunology platform to autoimmune diseases, testing two nove
Sep 14, 2026
BEARISH6-K5/10
Evaxion A/S raised $2.1M net through an at-the-market (ATM) offering of 681,268 ADSs at an average p
Sep 4, 2026
NEUTRAL6-K4/10
Evaxion reported Q2 2026 results in line with expectations: net loss narrowed to $3.7M (vs $4.8M YoY
Aug 20, 2026
NEUTRALPRESS-RELEASE4/10
Evaxion reported Q2 2026 net loss of $3.7M, in line with expectations and improved from $4.8M a year
Aug 20, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 2, 2026
announcement
Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting
COPENHAGEN, Denmark, October 2, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with
Aug 20, 2026
earnings
Evaxion announces business update and second quarter 2026 financial results
COPENHAGEN, Denmark, August 20, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pio
Aug 20, 2026
earnings_calendar
EVAX Q2 2026 Earnings Scheduled — 2026-08-20
Aug 20, 2026
short_volume
Short Volume: EVAX — 57.3% short (0.3M / 0.6M)
Short: 340,218 | Exempt: 2,154 | TRF Vol: 593,726 | Short Ratio: 57.3% | Off-exchange volume (dark pool + OTC)
Aug 20, 2026
ftd
FTD: EVAX — 196,368 shares ($0.6M) failed to deliver
Settlement: 20260820, Price: $3.15, FTD Value: $618,559.2, EVAXION A/S AMERICAN DEPOSITAR
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.01 | $-0.01–$-0.01 | -200.0% | +0.0% | — | $0.0B | 1 |
| Next Q | $-0.01 | $-0.01–$-0.01 | 0.0% | +0.0% | — | $0.0B | 1 |
| Current FY | $-0.04 | $-0.04–$-0.04 | -100.0% | +0.0% | — | $0.0B | 2 |
| Next FY | $-0.01 | $-0.03–$0.00 | 62.5% | -137.5% | 0↑ 1↓ | $0.0B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.010 | — |
| 7d ago | $-0.010 | — |
| 30d ago | $-0.010 | — |
| 60d ago | $-0.010 | — |
| 90d ago | $-0.010 | — |
Institutional ownership
Which big funds own EVAX (from quarterly 13F filings) and who is adding or trimming.
8 institutional holders with $537.7K total value (173,454 shares) as of 2026-Q2. Top holders: Rathbones, CITADEL, RENAISSANCE. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| Rathbones Group PLC | 45,723 | $141.7K | 26.4% | — |
| CITADEL ADVISORS LLC | 36,584 | $113.4K | 21.1% | DOUBLED +105.8% |
| RENAISSANCE TECHNOLOGIES LLC | 33,800 | $104.8K | 19.5% | — |
| RHUMBLINE ADVISERS | 21,849 | $67.7K | 12.6% | DOUBLED +123.5% |
| JANE STREET GROUP, LLC | 20,581 | $63.8K | 11.9% | — |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 8,000 | $24.8K | 4.6% | — |
| UBS Group AG | 6,275 | $19.5K | 3.6% | DOUBLED +321600.0% |
| Integrated Wealth Concepts LLC | 642 | $2.0K | 0.4% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| CITADEL ADVISORS LLC | DOUBLED | 17,773 | 36,584 | +105.8% | $113.4K |
| RHUMBLINE ADVISERS | DOUBLED | 9,435 | 21,090 | +123.5% | $100.6K |
| UBS Group AG | DOUBLED | 1 | 3,217 | +321600.0% | $15.3K |
| UBS Group AG | NEAR_EXIT | 2,039 | 1 | -100.0% | $4.00 |
| RHUMBLINE ADVISERS | DOUBLED | 2,208 | 9,435 | +327.3% | $23.1K |
| UBS Group AG | TRIM | 6,517 | 2,039 | -68.7% | $5.0K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for EVAX.
Shares short
53,784
Settlement Sep 15, 2026
Change vs prior
-4.8%
Semi-monthly cycle
Days to cover
1.1
At avg daily volume
Of shares outstanding
≈0.6%
Estimate — not % of float
All EVAX filing & press-release reports (36)
- 6-K reportSep 14, 2026
- 6-K reportSep 4, 2026
- 6-K reportAug 20, 2026
- PRESS-RELEASE reportAug 20, 2026
- 6-K reportAug 17, 2026
- 6-K reportAug 14, 2026
- PRESS-RELEASE reportAug 14, 2026
- 6-K reportJul 17, 2026
- PRESS-RELEASE reportJul 17, 2026
- 6-K reportJul 13, 2026
- PRESS-RELEASE reportJul 12, 2026
- 6-K reportJul 3, 2026
- PRESS-RELEASE reportJul 1, 2026
- 6-K reportJun 12, 2026
- PRESS-RELEASE reportJun 12, 2026
- 6-K reportJun 11, 2026
- PRESS-RELEASE reportJun 11, 2026
- PRESS-RELEASE reportMay 12, 2026
- 6-K reportMay 12, 2026
- 6-K reportMay 7, 2026
- PRESS-RELEASE reportMay 4, 2026
- 6-K reportApr 27, 2026
- PRESS-RELEASE reportApr 27, 2026
- 6-K reportApr 22, 2026
- 6-K reportApr 17, 2026
- 6-K reportApr 17, 2026
- PRESS-RELEASE reportApr 17, 2026
- PRESS-RELEASE reportApr 17, 2026
- 6-K reportApr 16, 2026
- PRESS-RELEASE reportApr 16, 2026
- PRESS-RELEASE reportApr 7, 2026
- PRESS-RELEASE reportMar 19, 2026
- PRESS-RELEASE reportMar 17, 2026
- PRESS-RELEASE reportMar 5, 2026
- PRESS-RELEASE reportMar 5, 2026
- PRESS-RELEASE reportMar 2, 2026